Navigation Links
AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
Date:5/3/2013

REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2013 financial results after market close on Wednesday, May 8, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on May 8, 2013 to discuss the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link in the Event Calendar page.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investors page of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced resul
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
2. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
3. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
4. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
5. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
6. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. AcelRx Pharmaceuticals Provides Clinical Trial Updates
8. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
9. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
11. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  ViaCyte, Inc., a ... therapy for the treatment of diabetes in clinical trials, today announced ... called STEP ONE, or S afety, T olerability, and ... One Diabetes.  The new site, which is the first ... of Alberta Hospitals in Edmonton , Alberta.  ...
(Date:7/29/2015)... July 27, 2015 Research ... the "Pharmaceutical Packaging Market by Packaging Type, by ... Europe, Asia-Pacific, RoW) - Forecasts to 2020" report ... market demand, by value is estimated to reach above ... market is anticipated to show a steady growth rate ...
(Date:7/29/2015)... , July 29, 2015 KaloBios Pharmaceuticals, ... focused on developing innovative therapies to benefit patients with ... oncology, announced today that it received a formal determination ... the company that it is now compliant with the ... NASDAQ Global Market and is no longer subject to ...
Breaking Medicine Technology:ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 2Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 2KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 4
... CYBX ) today announced that Dan Moore, President and ... present at the 22nd Annual Piper Jaffray Health Care Conference ... PM ET.  The conference session and webcast will be audio ... will host a webcast of the presentation live and by ...
... Patients with Chronic Obstructive Pulmonary Disease, or COPD, ... burden they must deal with and as a loss ... by GlaxoSmithKline.  Patients participating in the research characterized their ... loss of energy, loss of control, loss of independence ...
Cached Medicine Technology:Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference 2COPD Patients Reveal Disease Progression Leads to Physical and Social Isolation and Increased Reliance on the Internet(1) 2COPD Patients Reveal Disease Progression Leads to Physical and Social Isolation and Increased Reliance on the Internet(1) 3
(Date:7/29/2015)... ... July 29, 2015 , ... Orthopedic surgeons at Lourdes Medical Center of ... Rotator Cuff System, a new implant to treat a common source of shoulder pain ... regeneration of additional tendon tissue, which could allow for faster healing and a decreased ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty prep ... looking good on the big day. Every bride wants to look and feel beautiful, but ... , According to a recent study by the American Academy of Facial ...
(Date:7/29/2015)... ... July 29, 2015 , ... Fastline ... fall of 2015 on RFD-TV. , Fastline is dedicated to quality agricultural advertising, ... which contains the largest and freshest searchable agriculture equipment database in the world. ...
(Date:7/29/2015)... ... 2015 , ... A June 10, 2015 article from the News-Press, entitled " ... of having regular skin cancer screenings from an early age. Skin cancer can strike ... caught early, skin cancer is rarely fatal; however, if left alone for too long, ...
(Date:7/29/2015)... Madison, Wis. (PRWEB) , ... July 29, 2015 ... ... enrolled its first two patients in a Clinical Performance Study for the Invisiport ... includes 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative ...
Breaking Medicine News(10 mins):Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3Health News:Fastline Publications to Partner with American Farmer in Upcoming Episode Airing on RFD-TV 2Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3
... Goodwin HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay ... the death of a child in infancy have an increased ... suggests. Researchers from the United Kingdom looked at census ... child between 1971 and 2006 or whose child died before ...
... at the University of Toronto have developed a therapy ... catheters, artificial joints and other "in-dwelling" medical devices. Their ... Pathogens on September 8th. The therapy targets ... devices because they are composed of biofilmscomplex groupings of ...
... September 7, 2011 (BRONX, NY) In 2004, the ... in Africa. As a result, millions of Africans are now ... been available in the developed world. While research shows that ... about the actual deployment and circumstances of treatment. ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- ... rise, reaching 22.6 million, or 8.9 percent of the population, ... has largely been driven by more marijuana use, according to ... fact, in 2010 some 17.4 million Americans were using marijuana, ...
... given before or after breast-conserving therapy (BCT) does not ... success is due more to biologic factors than chemotherapy ... University of Texas MD Anderson Cancer Center. Presented ... also found that neoadjuvant chemotherapy (given before surgery), often ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) ... when the hijacked planes with their terrified passengers ripped into ... are incomplete, they,re burned into her memory just the same. ... mother glued to the TV, watching the Twin Towers collapse. ...
Cached Medicine News:Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 3Health News:Combination therapy rids common infection from implanted medical devices 2Health News:Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa 2Health News:More U.S. Adults Using Illegal Drugs: Report 2Health News:More U.S. Adults Using Illegal Drugs: Report 3Health News:Chemotherapy is as effective before breast cancer surgery as after 2Health News:9/11 a Life-Defining Day for the Young 2Health News:9/11 a Life-Defining Day for the Young 3Health News:9/11 a Life-Defining Day for the Young 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: